New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export BMY’s income statement to Excel — free account
Bristol Myers Squibb Company
BMYHealthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- +6.93%
- EPS
- −2.78%
- Free cash flow
- −36.0%
- Total debt
- −12.5%
Quarter to September 2026, against a year earlier
59.43
1.09
+1.87%
Follow BMY
Alert me
Revenue to profit Twelve months to Sep 30, 2026
Of every $100 of revenue, $18.47 was left as profit. Gross margin has fallen three quarters running, from 71.1% to 69.2%. What is an income statement?
| Revenue | 50.0 | 100.0% |
|---|---|---|
| Cost of revenue | −15.4 | −30.8% |
| Gross profit | 34.6 | 69.2% |
| Research & development | −10.6 | −21.1% |
| Selling, general & admin | −7.3 | −14.6% |
| Other operating costs | −5.4 | −10.9% |
| Operating income | 11.3 | 22.7% |
| Income tax | −2.1 | −4.2% |
| Net income | 9.2 | 18.5% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $48.2B | $48.5B | $49.2B | $50.0B |
| Operating income | $9.3B | $9.6B | $11.9B | $11.3B |
| Net income | $7.1B | $7.3B | $9.3B | $9.2B |
| Net margin (right axis) | 14.6% | 15.0% | 18.9% | 18.5% |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Revenue |
+8 more TTM periods Free account |
48,194.00 | 48,482.00 | 49,186.00 | 50,033.00 |
Cost of Revenue |
13,936.00 | 14,324.00 | 14,678.00 | 15,389.00 | |
Gross Profit |
34,258.00 | 34,158.00 | 34,508.00 | 34,644.00 | |
R&D Expenses |
9,951.00 | 10,343.00 | 10,722.00 | 10,559.00 | |
SG&A Expenses |
7,267.00 | 7,300.00 | 7,413.00 | 7,323.00 | |
Operating Income |
9,328.00 | 9,597.00 | 11,911.00 | 11,333.00 | |
| 9,328.00 | 9,597.00 | 11,910.00 | 11,332.00 | ||
Income Tax Provision |
2,272.00 | 2,324.00 | 2,634.00 | 2,089.00 | |
Income after Tax |
7,056.00 | 7,273.00 | 9,276.00 | 9,243.00 | |
Non-Controlling Interest |
1.00 | (4.00) | (7.00) | (1.00) | |
Net Income Common |
7,054.00 | 7,275.00 | 9,282.00 | 9,243.00 | |
EPS (Basic) |
3.46 | 3.56 | 4.54 | 4.52 | |
EPS (Diluted) |
3.45 | 3.56 | 4.54 | 4.51 | |
Shares (Basic, Weighted) |
2,034.00 | 2,035.75 | 2,037.50 | 2,039.25 | |
Shares (Diluted, Weighted) |
2,039.00 | 2,040.75 | 2,043.25 | 2,046.75 | |
Gross Margin |
71.08% | 70.46% | 70.16% | 69.24% | |
EBIT Margin |
19.36% | 19.79% | 24.22% | 22.65% | |
EBT margin |
19.36% | 19.79% | 24.21% | 22.65% | |
Net Profit Margin |
14.64% | 15.01% | 18.87% | 18.47% | |
Free Cash Flow Margin |
26.65% | 24.56% | 23.26% | 18.56% | |
EBITDA |
13,339.00 | 13,190.00 | 15,087.00 | 14,124.00 | |
EBIT |
9,328.00 | 9,597.00 | 11,911.00 | 11,333.00 | |
EPS (Diluted, from Cont. Ops) |
3.46 | 3.56 | 4.54 | 4.51 | |
EPS (Diluted, Consolidated) |
3.46 | 3.56 | 4.54 | 4.51 | |
EPS (Basic, Consolidated) |
3.47 | 3.57 | 4.55 | 4.53 | |
Shares (Diluted, Average) |
2,039.50 | 2,041.25 | 2,043.75 | 2,047.25 | |
EPS (Basic, from Continuous Ops) |
3.47 | 3.57 | 4.55 | 4.53 | |
Income from Continuous Operations |
7,056.00 | 7,273.00 | 9,276.00 | 9,243.00 | |
Consolidated Net Income/Loss |
7,056.00 | 7,272.00 | 9,275.00 | 9,242.00 | |
EBITDA Margin |
27.68% | 27.21% | 30.67% | 28.23% | |
Operating Cash Flow Margin |
29.37% | 27.45% | 25.99% | 21.29% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026